Pharmacologic Management of Chronic Obstructive Pulmonary Disease

Publication Date: April 1, 2020
Last Updated: July 31, 2023

Treatment

In patients with COPD who complain of dyspnea or exercise intolerance, the ATS2 recommends long-acting β-agonist (LABA)/long-acting muscarinic antagonist (LAMA) combination therapy over LABA or LAMA monotherapy. ( S )
621

Video


Overview

Title

Pharmacologic Management of Chronic Obstructive Pulmonary Disease

Authoring Organization